HSD17B4 and breast cancer: As a marker to predict pCR to trastuzumab and chemotherapy against HER2-positive breast cancer, HSD17B4 methylation was successfully identified by genome-wide methylation analysis, and was validated by analysis of an independent validation set of samples (P < 0.001).